Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of LGEV1801 and LGEV1802 in Healthy Volunteers
NCT03532854Phase 1Completed
- Sponsor
- LG Chem
- Start
- May 2018
- Primary completion
- Aug 2018
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of valsartan, ezetimibe and rosuvastatin in hypertension (HTN) and dyslipidemia (6 arms), sponsored by LG Chem. Primary endpoints: Area Under the Concentration-Time Curve at Steady State and Maximum Plasma Concentration at Steady State. Started May 2018; status: completed.
02
Drugs
valsartanezetimiberosuvastatin
03
Conditions
hypertension (HTN)dyslipidemia
Beyond the preview
Go deeper on NCT03532854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03532854.